Drug Profile


Alternative Names: HN 770; HSR 770; HY 770; Inaperisone hydrochloride; Riran; YM 170

Latest Information Update: 22 Dec 1999

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hokuriku Seiyaku
  • Developer Hokuriku Seiyaku; Yamanouchi
  • Class Propiophenones; Small molecules
  • Mechanism of Action Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Muscle hypertonia; Urinary incontinence

Most Recent Events

  • 22 Dec 1999 Discontinued-preregistration for Urinary incontinence in Japan (PO)
  • 20 May 1998 Discontinued-preregistration for Hypertonia in Japan (PO)
  • 02 Feb 1998 No-Development-Reported for Hypertonia in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top